Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year per ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Through a combination of academic rigor, innovative AI applications, and cross-disciplinary collaboration, Dr. Ravikanth ...

Tilt your stock portfolio toward biotech companies now and you could stand to make substantial profits in the near future. You can also find cost-effective stocks under $20 to trade daily on the ...

Philippe Masset has been appointed to the Board of Directors at Vect-Horus, a French biotech developing vectors for targeting ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

Although UnitedHealth Group is one of the largest healthcare companies, it has faced reputational ... AstraZeneca is a multinational biotech company that was formed through the 1999 merger of ...